Uutisia, analyysejä ja markkinakalenteri

Nasdaq

Veloxis Pharmaceuticals A/S15 min viivästetty

Muutos-2.87% Viimeisin0,84 DKK
Osto Myynti Lue lisää
		

Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer

08:00 Veloxis Pharmaceuticals A/S Changes board/management/auditors Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer Company Release no. 19/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 13 September 2017 Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer Veloxis Pharmaceuticals A/S is pleased to announce that Veloxis Pharmaceuticals, Inc. has hired Ulf Meier-Kriesche, MD, to serve as its Chief Scientific Officer. In this role, Dr. Meier-Kriesche will oversee the Companys regulatory and medical affairs departments. Dr. Meier-Kriesche is a board certified Nephrologist with over 20 years of practical clinical experience in transplantation. He is the author of over 170 scientific publications that have appeared in numerous peer-reviewed journals. Additionally, Dr. Meier-Kriesche served on the faculty of the University of Florida Medical School from 2001 until 2011. Prior to joining Veloxis, Dr. Meier-Kriesche was the Clinical Trials Lead Immunology at Bristol-Myers Squibb. Dr. Meier-Kriesche has also worked for Astellas Pharma. Craig Collard, CEO of Veloxis Pharmaceuticals A/S said Veloxis is committed to serving the needs of the transplant community and the appointment of Ulf Meier-Kriesche further solidifies that commitment. Ulfs background and experience as a transplant nephrologist will help Veloxis be more responsive to the concerns of clinicians and ultimately better support the transplant community. Ulf Meier-Kriesche commented I am thrilled to join Veloxis because of the wonderful opportunity we have together to bring new therapeutic options to transplant patients. For more information, please contact: Craig A. Collard President & CEO Phone: +1 919 591 3090 Email: cac@veloxis.com About Veloxis Pharmaceuticals Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the companys unique and patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. For further information, please visit www.veloxis.com. © Nasdaq
Nordnetissä voit säästää ja sijoittaa osakkeisiin, rahastoihin, ETF:iin ja muihin tuotteisiin. Ilman kiinteitä kustannuksia ja edulliseen hintaan.

Rahoitusvälineiden arvo voi nousta tai laskea. On olemassa riski, ettet saa sijoittamiasi varoja takaisin. Historiallinen kehitys ei ole tae tulevasta tuotosta. Sinun tulee perehtyä rahastoesitteeseen ja avaintietoesitteeseen ennen kuin sijoitat rahastoihin. Rahastoesitteen saat rahastoyhtiöltä ja avaintietoesitteen löydät nordnet.fi-sivustolta rahaston yleiskatsaus -sivulta sekä toimeksiantosivulta.